HARRISON, NY / ACCESSWIRE / March 14, 2019 / –Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today that the company will present preclinical data on its ST101 program at the American Association for Cancer Research (AACR) annual meeting. The conference will take place in Atlanta, GA from March 29 – April 3, 2019.
Details of the poster abstract are as follows:
Abstract Title: Cell penetrating peptide, ST101, disrupts ATF5 regulation of anti-apoptotic Bcl-2 family proteins, resulting in induction of cancer cell death in vitro and tumor growth inhibition/regression in vivo
Session Category: Experimental and Molecular Therapeutics
Session Title: Apoptosis, Necrosis, and Cancer Cell Survival
Date and Time: Monday, Apr 1 2019, from 1:00 – 5:00 PM EST
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 9
Poster Board Number: 2
Abstract Number: 2050
About Sapience Therapeutics
Sapience Therapeutics, Inc., is a privately held, preclinical biotechnology company focused on discovering and developing peptide-based therapeutics for major unmet medical needs, particularly high mortality cancers. With platform-based discovery of peptide therapeutics that disrupt protein:protein interactions, Sapience’s molecules hold potential to target intracellular interactions that are traditionally considered ”undruggable targets”. Its lead compound, ST101, is a first-in-class molecule with potential applications in various solid tumors and hematologic malignancies. In 2016, Sapience Therapeutics closed its Series A financing, which was led by Eshelman Ventures and included investments from Celgene Corporation, TaiAn Technologies Corporation and Healthlink Capital. For more information on Sapience Therapeutics, please visit www.sapiencetherapeutics.com.
This press release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties. These statements are based on management’s current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, risks related to the application of the net proceeds from the offering to Sapience’s product development objectives, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. These are forward-looking statements, which speak only as of the date of this press release. Sapience does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.
Sapience Therapeutics, Inc.:
President and Chief Executive Officer
SOURCE: Sapience Therapeutics, Inc.
Released March 14, 2019